Featured Research

from universities, journals, and other organizations

New device for treating atrial fibrillation

Date:
February 27, 2014
Source:
Loyola University Health System
Summary:
A new high-tech catheter device can improve outcomes of patients treated for atrial fibrillation, the most common irregular heartbeat. The treatment, called catheter ablation, involves burning selected spots of tissue inside the heart with the tip of a catheter. This eliminates the sources of errant electrical signals that are triggering the atrial fibrillation. More than 2 million Americans have atrial fibrillation, also known as a-fib. There are about 160,000 new cases each year. The number is increasing due in part to the aging population and the obesity epidemic.

Loyola University Medical Center is the first hospital in Illinois to offer a new high-tech catheter device that can improve outcomes of patients treated for atrial fibrillation, the most common irregular heartbeat.

The treatment, called catheter ablation, involves burning selected spots of tissue inside the heart with the tip of a catheter. This eliminates the sources of errant electrical signals that are triggering the atrial fibrillation.

The new device, the ThermoCool® SmartTouch® catheter, has just been approved by the U.S. Food and Drug Administration. The device tells the physician the precise direction of the catheter and how hard it is pushing against the heart wall. This information is graphically displayed on a 3-D mapping and navigation system.

Loyola participated in a pivotal, multicenter clinical trial of the pressure-sensing catheter. Principal investigator at the Loyola site was David Wilber, MD, one of the nation's leading researchers in treating atrial fibrillation. Wilber is director of Loyola's Division of Cardiology and Section of Clinical Electrophysiology.

In a-fib, electrical signals that regulate the heartbeat become erratic. Instead of beating regularly, the upper chambers of the heart quiver. Not all the blood gets pumped out, so clots can form. A-fib can lead to strokes and heart failure.

More than 2 million Americans have atrial fibrillation, also known as a-fib. There are about 160,000 new cases each year. The number is increasing due in part to the aging population and the obesity epidemic.

A-fib symptoms include heart palpitations, dizziness, chest pain, fatigue, shortness of breath, fainting and lightheadedness. "A lot of people are disabled," Wilber said. "They have no energy. They can't work. They have a very poor quality of life."

Medications can maintain a normal heart rhythm. But when drugs don't work or cause unacceptable side effects, alternative treatments include surgery or catheter ablation. While drugs have been available for more than 30 years, ablation is a relatively new treatment.

In catheter ablation, an electrophysiologist inserts a catheter (thin flexible tube) in a groin artery and guides it through blood vessels to the heart. The tip of the catheter delivers radiofrequency energy that heats and destroys tissue that is sending out erratic electrical signals.

The challenge is to press the catheter firmly enough against the wall of the heart so that sufficient tissue is destroyed, without pushing so hard that the catheter punches a hole in the heart. This requires a very fine balance that is difficult to achieve, even for an experienced physician.

In the new device, a sensor in the tip of the catheter enables direct measurement of both the amount of contact force and the angle in which the force is being applied to the heart wall.

"The pressure-sensing catheter can improve patient outcomes and the durability of ablation treatments," Wilber said.


Story Source:

The above story is based on materials provided by Loyola University Health System. Note: Materials may be edited for content and length.


Cite This Page:

Loyola University Health System. "New device for treating atrial fibrillation." ScienceDaily. ScienceDaily, 27 February 2014. <www.sciencedaily.com/releases/2014/02/140227163837.htm>.
Loyola University Health System. (2014, February 27). New device for treating atrial fibrillation. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2014/02/140227163837.htm
Loyola University Health System. "New device for treating atrial fibrillation." ScienceDaily. www.sciencedaily.com/releases/2014/02/140227163837.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) — Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) — The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) — Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) — New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins